Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 32, Number 3—March 2026
Dispatch
Tuberculosis after TB Preventive Therapy in Persons Living with HIV Recently Initiating Antiretroviral Therapy, Mozambique
Lindsay Templin
, Yagna Varajidas, Durval Respeito, Pereira Zindoga, Debora Weiss, Alexandre Nguimfack, Eudoxia Filipe, Arlete Mahumane, Maria Inês Tomo de Deus, José Mizela, Sonia Chilundo, Bruno Simoes, Aleny Couto, Ishani Pathmanathan, Emilio Dirlikov, and Benedita José
, Yagna Varajidas, Durval Respeito, Pereira Zindoga, Debora Weiss, Alexandre Nguimfack, Eudoxia Filipe, Arlete Mahumane, Maria Inês Tomo de Deus, José Mizela, Sonia Chilundo, Bruno Simoes, Aleny Couto, Ishani Pathmanathan, Emilio Dirlikov, and Benedita José
Table 3
Incidence of TB among PLHIV newly initiated on ART who completed TPT, Mozambique, 2021–2024*
| Characteristic | TB positive | Person-years | Incidence rate (95% CI) | Univariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|---|---|---|---|
| IRR (95% CI) | p value | IRR (95% CI) | p value | |||||
| Sex | ||||||||
| F | 803 | 313,190 | 2.6 (2.4–2.7) | Referent | Referent | |||
| M |
747 |
179,645 |
4.2 (3.9–4.5) |
1.6 (1.5–1.8) |
<0.001 |
1.54 (1.4–1.7) |
<0.001 |
|
| Viral load result† | ||||||||
| Suppressed | 1,316 | 458,416 | 2.9 (2.7–3.0) | Referent | Referent | |||
| Not suppressed |
234 |
34,419 |
6.8 (6.0–7.7) |
2.4 (2–2.7) |
<0.001 |
2.35 (2–2.7) |
<0.001 |
|
| Age group | ||||||||
| 15–49 | 1,197 | 427,626 | 2.8 (2.6–3.0) | Referent | Referent | |||
| <15 | 118 | 23,783 | 5.0 (4.1–5.9) | 1.8 (1.5–2.2) | <0.001 | 1.50 (1.2–1.8) | <0.001 | |
| ≥50 |
235 |
41,425 |
5.7 (5.0–6.4) |
2.0 (1.7–2.3) |
<0.001 |
1.72 (1.5–2) |
<0.001 |
|
| TPT regimen | ||||||||
| Isoniazid | 1,371 | 461,601 | 3.0 (2.8–3.1) | Referent | Referent | |||
| 3HP |
179 |
31,234 |
5.7 (4.9–6.6) |
1.9 (1.6–2.3) |
<0.001 |
1.07 (0.9–1.3) |
0.54 |
|
| Health facility setting | ||||||||
| Rural | 872 | 305,777 | 2.9 (2.7–3) | Referent | Referent | |||
| Urban |
678 |
187,058 |
3.6 (3.4–3.9) |
1.3 (1.1–1.5) |
<0.001 |
1.12 (1–1.3) |
0.14 |
|
| Region‡ | ||||||||
| Northern | 416 | 159,095 | 2.6 (2.4–2.9) | Referent | Referent | |||
| Central | 533 | 205,089 | 2.6 (2.4–2.8) | 1.0 (0.8–1.2) | 0.95 | 1.05 (0.9–1.3) | 0.60 | |
| Southern |
601 |
128,651 |
4.7 (4.3–5.1) |
1.8 (1.5–2.1) |
<0.001 |
1.58 (1.3–1.9) |
<0.001 |
|
| Latest CD4 result | ||||||||
| ≥200 cells/mm3 | 301 | 58,421 | 5.2 (4.6–5.8) | Referent | Referent | |||
| <200 cells/mm3 | 160 | 13,622 | 11.7 (10–13.7) | 2.3 (1.9–2.8) | <0.001 | 1.87 (1.5–2.3) | <0.001 | |
| Not Tested |
1,089 |
420,792 |
2.6 (2.4–2.7) |
0.5 (0.4–0.6) |
<0.001 |
0.57 (0.5–0.7) |
<0.001 |
|
| WHO staging status at ART start | ||||||||
| Stage I | 1,105 | 403,014 | 2.7 (2.6–2.9) | Referent | Referent | |||
| Stage II | 268 | 60,760 | 4.4 (3.9–5) | 1.6 (1.4–1.9) | <0.001 | 1.55 (1.3–1.8) | <0.001 | |
| Stage III | 131 | 18,502 | 7.1 (5.9–8.4) | 2.6 (2.2–3.1) | <0.001 | 2.46 (2.1–2.9) | <0.001 | |
| Stage IV | 18 | 2,993 | 6.0 (3.6–9.5) | 2.2 (1.4–3.5) | <0.001 | 1.70 (1.1–2.7) | <0.001 | |
| Not recorded |
28 |
7,566 |
3.7 (2.5–5.3) |
1.3 (0.9–2) |
0.13 |
1.41 (1–2.1) |
0.08 |
|
| Started TPT within 30 d of ART initiation | ||||||||
| TPT at ART start | 1,446 | 466,832 | 3.1 (2.9–3.3) | Referent | Referent | |||
| Delayed TPT start | 104 | 26,003 | 4.0 (3.3–4.8) | 1.3 (1.1–1.6) | <0.001 | 1.02 (0.8–1.2) | 0.88 | |
*Incidence is cases/1,000 person-years. IRR, incidence rate ratio, TPT, TB prevention therapy, 3HP, 3-month course of 12 (1/wk) doses of isoniazid and rifapentine. †Suppressed, <1,000 copies/mL; unsuppressed, >1,000 copies/mL. ‡Mozambique’s 11 provinces are categorized into 3 regions: Central (Sofala, Manica, Tete, Zambezia), Northern (Nampula, Niassa, Cabo Delgado), and Southern (Maputo City, Maputo, Gaza, Inhambane).
Page created: February 13, 2026
Page updated: February 26, 2026
Page reviewed: February 26, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.